The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Autor: | Antonio Pérez-Martínez, Ana Patiño-García, Alba Rubio-San-Simón, Palma Solano, Jaime Verdú-Amorós, R. Hladun Alvaro, A. Castañeda Heredia, Manuel Ramírez, Francisco Bautista, Cristina Mata, Ofelia Cruz, Mara Andrés, Jaume Mora, L. Moreno, Javier Martin-Broto, A. Llort, Adela Cañete, A. Morales La Madrid, Susana Rives, A. Fernández‑Teijeiro, Soledad Gallego, Pilar Guerra-García, A. Lassaleta, I. Martínez Romera, A. Juan Ribelles |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Adult Cancer Research medicine.medical_specialty Adolescent Paediatric haematology Paediatric haematology and oncology Drug development Medical Oncology Pediatrics Access to innovation Clinical research 03 medical and health sciences Young Adult 0302 clinical medicine Clinical trials Paediatric cancer Neoplasms Medicine Humans Longitudinal Studies Child Societies Medical Clinical Trials as Topic business.industry Paediatric oncology General Medicine Clinical trial 030104 developmental biology Country study Oncology 030220 oncology & carcinogenesis Family medicine Access to innovation Clinical research Clinical trials Drug development Paediatric haematology and oncology Early phase business Follow-Up Studies |
Zdroj: | CLINICAL & TRANSLATIONAL ONCOLOGY r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
ISSN: | 1699-048X |
Popis: | PURPOSE: Early phase trials are crucial in developing innovative effective agents for childhood malignancies. We report the activity in early phase paediatric oncology trials in Spain from its beginning to the present time and incorporate longitudinal data to evaluate the trends in trial characteristics and recruitment rates. METHODS: Members of SEHOP were contacted to obtain information about the open trials at their institutions. The study period was split into two equal periods for analysis: 2007-2013 and 2014-2020. RESULTS: Eighty-one trials and two molecular platforms have been initiated. The number of trials has increased over the time of the study for all tumour types, with a predominance of trials available for solid tumours (66%). The number of trials addressed to tumours harbouring specific molecular alterations has doubled during the second period. The proportion of industry-sponsored compared to academic trials has increased over the same years. A total of 565 children and adolescents were included, with an increasing trend over the study period. For international trials, the median time between the first country study approval and the Spanish competent authority approval was 2 months (IQR 0-6.5). Fourteen out of 81 trials were sponsored by Spanish academic institutions. CONCLUSIONS: The number of available trials, and the number of participating patients, has increased in Spain from 2007. Studies focused on molecular-specific targets are now being implemented. Barriers to accessing new drugs for all ranges of age and cancer diseases remain. Additionally, opportunities to improve academic research are still required in Spain. |
Databáze: | OpenAIRE |
Externí odkaz: |